Menter Alan, Korman Neil J, Elmets Craig A, Feldman Steven R, Gelfand Joel M, Gordon Kenneth B, Gottlieb Alice B, Koo John Y M, Lebwohl Mark, Lim Henry W, Van Voorhees Abby S, Beutner Karl R, Bhushan Reva
Baylor University Medical Center, Dallas, Texas, USA.
J Am Acad Dermatol. 2009 Sep;61(3):451-85. doi: 10.1016/j.jaad.2009.03.027. Epub 2009 Jun 3.
Psoriasis is a common, chronic, inflammatory, multisystem disease with predominantly skin and joint manifestations affecting approximately 2% of the population. In this fourth of 6 sections of the guidelines of care for psoriasis, we discuss the use of traditional systemic medications for the treatment of patients with psoriasis. Treatment should be tailored to meet individual patients' needs. We will discuss in detail the efficacy and safety, and offer recommendations for the use of the 3 most commonly used, and approved, traditional systemic agents: methotrexate, cyclosporine, and acitretin. We will also briefly discuss the available data for the use of azathioprine, fumaric acid esters, hydroxyurea, leflunomide, mycophenolate mofetil, sulfasalazine, tacrolimus, and 6-thioguanine in psoriasis.
银屑病是一种常见的慢性炎症性多系统疾病，主要表现为皮肤和关节症状，影响约2%的人口。在本银屑病护理指南6个章节的第4部分中，我们讨论传统全身性药物在银屑病患者治疗中的应用。治疗应根据个体患者的需求进行调整。我们将详细讨论其疗效和安全性，并对3种最常用且已获批准的传统全身性药物：甲氨蝶呤、环孢素和阿维A的使用提供建议。我们还将简要讨论硫唑嘌呤、富马酸酯、羟基脲、来氟米特、霉酚酸酯、柳氮磺胺吡啶、他克莫司和6-硫鸟嘌呤在银屑病治疗中的现有数据。
